Dentsply Sirona (NASDAQ: XRAY) reported Q2 EPS of ($0.18), $0.16 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $490.6 million versus the consensus estimate of $492.55 million.

• Reported net sales of $491 million, down 51.4% vs. prior year, impacted by COVID-19. Organic sales declined 49.9% versus prior year
• Reported operating loss of $104 million. Non-GAAP operating loss of $42 million
• Reported EPS loss of $0.44. Non-GAAP EPS loss of $0.18

Don Casey, Chief Executive Officer of Dentsply Sirona, commented: “The global response to COVID-19 impacted our second quarter results. We have been encouraged to see continued improvement in sales trends, as dental offices reopen and patients return. To address the challenges posed by the pandemic, Dentsply Sirona has taken a number of steps focused on employee safety, customer service and securing the financial position of the Company. Today, to better position the Company for the future, we are initiating a series of additional restructuring actions that will enhance revenue growth, expand margins, and simplify the organization. As we embrace the current challenges, we remain optimistic about the future and we are confident in our strategy, our customers, and the Dentsply Sirona team.”

For earnings history and earnings-related data on Dentsply Sirona (XRAY) click here.